Novozymes
kr 419.50Change from previous close: +0.17%Absolute change: +kr 0.70
Valuation
Data as of October 2, 2026
Valuation multiples
- Market cap
- kr 192.65B
- Enterprise value
- kr 195.75B
- P/E (trailing 12 months)
- 40.7
- Forward P/E
- 23.1
- PEG
- 1.93
- Price/book
- 2.31
- Price/sales
- 44.8
- EV/EBITDA
- 121.6
- EV/revenue
- 45.6
Profitability and growth
- Gross margin
- 56.4%
- Operating margin
- 23.4%
- Net margin
- 14.7%
- ROE
- 5.8%
- ROA
- 3.8%
- Revenue growth (year over year)
- 9.6%
- Earnings growth (year over year)
- 26.7%
Financial health
- Total cash
- kr 308.7M
- Total debt
- kr 3.07B
- Debt/equity
- 0.28
- Current ratio
- 1.74
- Quick ratio
- 1.04
Dividends
- Annual dividend per share
- kr 6.60
- Dividend yield
- 1.6%
- Payout ratio
- 64.0%
- Ex-dividend date
- August 25, 2026
Analysts and estimates
- Average price target
- kr 499.27
- Median price target
- kr 500.00
- High price target
- kr 540.00
- Low price target
- kr 414.00
- Analysts with a price target
- 15
- Consensus
- Buy
- Forward EPS
- kr 17.87
- EPS estimate, current year
- kr 16.11
Shares and trading
- Beta
- 0.63
- Average volume
- 550.45K
- Shares outstanding
- 412.73M
- Float
- 347.61M
- Institutional ownership
- 37.1%
- Insider ownership
- 15.8%